

1 Imported SARS-COV-2 Variants of Concern Drove Spread of 2 Infections Across Kenya During the Second Year of the Pandemic

3
4 **Carolyn Nasimiyu^{1,2*}, Damaris Matoke-Muhia^{3*}, Gilbert K. Rono^{4*}, Eric Osoro^{1,2}, Daniel O.**
5 **Obado⁴, J. Milkah Mwangi³, Nicholas Mwikwabe³, Kelvin Thiong'o³, Jeanette Dawa¹, Isaac**
6 **Ngere¹, John Gachohi¹, Samuel Kariuki³, Evans Amukoye³, Marianne Mureithi⁵, Philip**
7 **Ngere⁶, Patrick Amoth⁶, Ian Were⁶, Lyndah Makayotto⁶, Vishvanath Nene⁴, Edward O.**
8 **Abworo⁴, M. Kariuki Njenga^{1,2,a}, Stephanie N. Seifert^{2,a}, Samuel O. Oyola^{4,a}**

9
10 ¹Washington State Global Health Program-Kenya, Washington State University, Nairobi,
11 Kenya, ²Paul G. Allen School for Global Health, Washington State University, Pullman, USA,
12 ³Kenya Medical Research Institute, Nairobi, Kenya, ⁴International Livestock Research
13 Institute, Nairobi, Kenya, ⁵Department of Medical Microbiology, University of Nairobi,
14 Nairobi, Kenya ⁶Kenya Ministry of Health, Nairobi, Kenya,

15
16 *These authors contributed equally

17 ^aJoint senior and corresponding authors

18 19 **CORRESPONDING AUTHORS:**

20 M. Kariuki Njenga, Mkariuki.njenga@wsu.edu, +254-700-354441

21 Samuel O. Oyola, s.oyola@cgiar.org, +254-724-567002

22 Stephanie N. Seifert, stephanie.seifert@wsu.edu, +1-509-335-3831

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **ABSTRACT**

24 **Background.** Using classical and genomic epidemiology, we tracked the COVID-19 pandemic
25 in Kenya over 23 months to determine the impact of SARS-CoV-2 variants on its progression.

26 **Methods.** SARS-CoV-2 surveillance and testing data were obtained from the Kenya Ministry
27 of Health, collected daily from 306 health facilities. COVID-19-associated fatality data were
28 also obtained from these health facilities and communities. Whole SARS-CoV-2 genome
29 sequencing were carried out on 1241 specimens.

30 **Results.** Over the pandemic duration (March 2020 - January 2022) Kenya experienced five
31 waves characterized by attack rates (AR) of between 65.4 and 137.6 per 100,000 persons,
32 and intra-wave case fatality ratios (CFR) averaging 3.5%, two-fold higher than the national
33 average COVID-19 associated CFR. The first two waves that occurred before emergence of
34 global variants of concerns (VoC) had lower AR (65.4 and 118.2 per 100,000). Waves 3, 4,
35 and 5 that occurred during the second year were each dominated by multiple introductions
36 each, of *Alpha* (74.9% genomes), *Delta* (98.7%), and *Omicron* (87.8%) VoCs, respectively.
37 During this phase, government-imposed restrictions failed to alleviate pandemic
38 progression, resulting in higher attack rates spread across the country.

39 **Conclusions.** The emergence of *Alpha*, *Delta*, and *Omicron* variants was a turning point that
40 resulted in widespread and higher SARS-CoV-2 infections across the country.

41

42 **KEY WORDS:** COVID-19 pandemic, variants of concern, attack rates

43 **RUNNING TITLE:** Genomic Epidemiology of COVID-19 in Kenya

44 **WORD COUNT:** ABSTRACT 208, TEXT 3520

45 **BACKGROUND**

46 In most countries globally, the COVID-19 pandemic progressed in a series of waves
47 characterized by rapid increase in infection rates followed by a few months of decline
48 before the next wave [1]. Factors associated with emergence of new waves included
49 declined application of mitigation measures, climatic changes, and emergence of new virus
50 variants [2,3]. The global genomic surveillance of SARS-CoV-2 played a pivotal role in
51 identifying emerging variants and associated mutations that impacted virus transmissibility,
52 disease severity, vaccine efficacy and clinical case management [3,4] . So far, key variants of
53 public health importance, designated by World Health Organization (WHO) as variants of
54 concern (VoC), had mutations that enhance transmissibility, reduced virus neutralization by
55 antibodies generated following infection or vaccination, interfered with diagnostic testing,
56 and often caused more severe disease [5]. These variants appeared to gain competitive
57 advantage on existing strains to exert immediate global dominance, and most were
58 associated with increased hospitalization or higher mortality, and re-infection of vaccinated
59 or previously infected persons [6].

60

61 The paucity of SARS-CoV-2 genomic surveillance data in Africa has limited our understanding
62 of role of virus variants in progression of COVID-19 pandemic in the continent. During the
63 early phase of the pandemic, epidemiologic data from the region suggested lower morbidity
64 and mortality in the region, attributed to factors such as youthful population, favorable
65 weather, and prior exposure to cross-reactive viruses [7]. However, later studies showed
66 infections rates comparable to global trends, but significantly lower levels of severe disease
67 and mortality [8]. The emergence of VoCs with global impact in the later phase of the
68 pandemic was associated with increased disease severity, rapid transmission, and re-

69 infection of vaccinated or previously infected persons, continuing to strain the global public
70 health infrastructure and economies despite availability of effective vaccines [9]. Among the
71 VoCs that had global impact were B.1.1.7 (*Alpha*) first identified in United Kingdom in
72 September 2020, B.1.351 (*Beta*) first reported in South Africa in December 2020, B.1.525
73 (*Eta*) first identified in the UK and Nigeria in December of 2020, B.1.617.1 (*Delta*) first
74 identified in India in October 2020, P.1 (or B.1.1.28.1, *Gamma*) first reported in Brazil in
75 January 2021, and B.1.1.529 (*Omicron*) first reported in South Africa in November
76 2021[4,10–12] and retroactively detected in samples in the US and other countries around
77 the same time [13]. Two other VOCs, B.1.427 and B1.429 (*Epsilon*) were detected in
78 California, United states in February 2021 but they did not have significant global spread
79 [14].

80
81 Progression of COVID-19 pandemic in Kenya may be classified into three phases. The first
82 phase (March 2020- February 2021) started with virus introduction into the country and
83 ended with emergence of VoCs. The second phase (March 2021 – October 2021) was
84 characterized by introduction of various VoCs and vaccination while most COVID-19
85 restriction remained in place. And the third phase (November 2021 – Present) started when
86 the government lifted most restrictions but also ensured vaccines were widely available.
87 Here, we tracked the pandemic in country over 23 months using classical and genomic
88 surveillance approaches in order to assess the impact of the emerging virus variants on
89 progression of the pandemic. Following confirmation of the first COVID-19 case on March
90 13, 2020, and through subsequent waves, the government of Kenya implemented various
91 mitigation measures to control its spread, including closure of international borders,
92 banning social gatherings, and lockdown of hotspots located primarily in urban and peri-

93 urban regions of the country [15]). Despite these measures, the SARS-CoV-2 prevalence in
94 capital city of Nairobi was reported as 35% in the first 8 month of the pandemic (in
95 November 2020) [16], and studies predicted that 75% of the Nairobi’s population would be
96 infected by June 2021[17].As at January 30, 2022, Kenya had reported five waves of COVID-
97 19 pandemic, with a total of 331,324 confirmed cases and 5,488 deaths (case fatality ratio =
98 1.7%)[18]. By then, only 17.3% of the adult population had been vaccinated, in large part
99 due to limited availability of vaccines, and a level of vaccine hesitancy [19–21].

100

101 **METHODS**

102 **COVID-19 surveillance data**

103 We abstracted data from the Kenya Ministry of Health (KMOH) COVID-19 daily situation
104 reports between March 12, 2020, and January 30, 2022[18]. The data collected included
105 date of report, number of confirmed cases and deaths at national and county level, age
106 group and sex of cases and deaths, and number of tests conducted. The KMOH situation
107 reports were based on the COVID-19 surveillance system that collected samples from
108 patients presenting at health facilities in 306 sub counties across the entire country and
109 meeting the suspect case definition for COVID-19. The surveillance system also collected
110 samples from healthcare workers with symptoms of a respiratory illness and/or meeting the
111 COVID-19 suspect case definition, people coming in-contact with confirmed COVID-19 cases,
112 and self-initiated testing at 50 biomedical laboratories for a variety of reasons such as
113 heightened suspicion index and international travel.

114 **SARS-CoV-2 testing and reporting**

115 From each surveilled individual, nasopharyngeal and oropharyngeal swabs were collected,
116 immediately preserved into virus transport medium (VTM), and transported in cool boxes to
117 any of about 200 designated COVID-19 testing laboratories within major hospitals and
118 biomedical research laboratories across the country. In most laboratories, three aliquots of
119 the sample were prepared, and one immediately tested for presence of SARS-CoV-2 virus
120 using RT-PCR. The other two aliquots were transferred to the Sample Management and
121 Receiving Facilities (SMRF) at the Kenya Medical Research Institute (KEMRI) for long-term
122 storage in -80°C. Testing laboratories reported results daily to the National Public Health
123 Laboratories at KMOH through an integrated laboratory information management system.

124 **SARS-CoV-2 testing inequity**

125 Nationally, the cumulative testing rate was 0.7 tests per 1000 persons per week, against a
126 target of 1 per 1000 persons per week as of January 30, 2022 [18]. The testing rate was
127 higher in the major cities of Nairobi, Mombasa, and other urban counties when compared
128 to rural counties. For example, between August and December 2021, the testing rate in
129 Nairobi was 4.7 tests per 1000 persons per week whereas in 9 rural counties the rate was
130 ~0.7 test per 1000 persons per week[18].

131 **Collection of fatality data**

132 COVID-19 related fatalities occurring within health facilities were reported daily through a
133 standard KMOH death reporting tool developed specifically for the pandemic. Fatalities
134 occurring within the communities were reported directly to 306 Sub-County Disease
135 Surveillance Coordinators (SCDSCs) nationally by the patient's relatives, community health
136 volunteers, or local government administrators in accordance Kenya Civil Registration Act.
137 All the SCDSCs in the country also collated and reported COVID-19 related mortality data
138 daily to Disease Surveillance and Response Unit at the KMOH national headquarters in
139 Nairobi.

140 **Epidemiology data analysis**

141 The reported COVID-19 cases and deaths were analyzed by week and county and presented
142 as counts, percentages, ranges, median and in epidemic curves. We defined a wave by epi-
143 week based on three criteria; i) increase in number of reported cases for three consecutive
144 weeks, ii) The start of the wave was the first week of at least three consecutive increases
145 where the increase from the previous week was at least 35%, and iii) the end of the wave
146 was defined as the week when the reported cases were equal to or lower than those
147 reported during the week of onset of the wave. The attack rate was defined as the number
148 of reported cases divided by the human population at national and county level. Case

149 fatality ratio (CFR) was defined as the ratio of deaths to reported cases. We estimated the
150 95% confidence interval of the proportion of cases and deaths on the binomial distribution
151 defined by the observed proportions.

152 **SARS-CoV-2 genomic surveillance**

153 Starting from May 2020, we selected up to 200 real-time PCR-positive specimens with C_T
154 ≤ 32.0 per month from the KEMRI SMRF for whole genome sequencing of SARS-CoV-2 at
155 either the Regional Genomic Center of International Livestock Research Institute (ILRI) or
156 Center for Biotechnology Research and Development of KEMRI.

157 **Whole genome sequencing and variant identification**

158 The SARS-CoV-2 whole genome sequencing was carried out as described previously
159 [22]. Briefly, viral RNA was extracted from sample either manually or using TANBead®
160 Maelstrom 9600 (Taiwan Advanced Nanotech Inc, Taiwan) automated nucleic acid extractor
161 according to the manufacturer's directions. For manual extraction, 140 μ l of sample was
162 applied in the QIAGEN QIAamp® Viral RNA Mini Kit (Hilden Düsseldorf, Germany). RNA was
163 eluted in 60 μ l buffer and stored in RNase-free Eppendorf tubes. The NEBNext-Artic SARS-
164 CoV-2 library preparation workflows for both Illumina and Oxford Nanopore Technologies
165 (ONT) were used [23]. For Illumina, the protocol NEBNext® ARTIC SARS-CoV-2 Library Prep
166 Kit (Illumina®) (Version 2.0_3/21) was used following manufacturer's instructions.
167 Sequencing was done on the Illumina MiSeq or NextSeq 550 platforms. Demultiplexing and
168 adapter trimming were performed automatically by the sequencing onboard software. For
169 ONT, the ARTIC SARS-CoV-2 Library Prep Kit (ONT®) were used. There was minimal deviation
170 with both Illumina and ONT workflows. Size distribution was estimated using agarose gel
171 electrophoresis. ONT sequencing was done on the MinION platform. Base calling,

172 demultiplexing and adapter trimming was performed using Guppy v5.0.11 and fastq outputs
173 used for downstream analyses.

174

175 Variant calling and lineage/clade assignment were carried out using the singularity container
176 of the nf-core/viralrecon v2.2: an analysis pipeline for assembly and intra-host/low-
177 frequency variant calling for viral samples[24] . Majorly, for Illumina, we used Fastp to trim
178 low-quality reads; Bowtie for read mapping, and iVar for removal of primer sequences,
179 mutation calling and for consensus generation. While with ONT data, read mapping and
180 consensus generation was by minimap2, and medaka was employed for mutation calling. In
181 both cases, snpEff was used for mutation annotation. The nf-core/viral recon ONT workflow
182 embeds the ARTIC ONT pipeline. Further downstream, consensus sequences were used by
183 Pangolin USHER for lineage assignments based on parsimony and Nextclade [25] for clade
184 specification.

185 **Phylogenetic analyses**

186 Apart from our sequences (n=1241), we downloaded an additional 894 complete SARS-CoV-
187 2 genomes from various lineages for phylogenomic comparison. To compare with global
188 sequences, consensus sequences were aligned using NextAlign, embedded in Nextclade, and
189 resulting multiple sequence alignment (MSA) fed into IQ-TREE [26] for inferring maximum
190 likelihood to determine the most likely phylogram describing the combined dataset. Tree
191 visualization and annotation were done using the FigTree software [27]. For time-resolved
192 phylogenetic trees, we used Mafft aligner v1.10.0[28] to generate MSA of the 1241
193 genomes. To account for homoplasy that may affect our phylogeny, we used the
194 ClonalFrameML [29] to estimate the phylogeny with corrected branch lengths.

195

196 Lineage designation was implemented in pangolin v 3.0 .1.17 [30] with USHER mode for
197 parsimony-based lineage assignment [31]. Multiple sequence alignment was performed on
198 SARS-CoV-2 sequences from all samples while separate alignments were performed for
199 *Delta* variants using NextAlign[32]. For both alignments, the maximum likelihood
200 phylogenetic tree was inferred using IQ-TREE v 2.1.3 [26] with ModelFinder [28] and 1000
201 UltraFast bootstrap replicate approximation[33] . The time-resolved phylogenetic tree for all
202 Kenya sequences was then inferred in TreeTime [34] with the Wuhan-Hu-1 variant (NCBI
203 reference: NC_045512.2) as the outlier. Phylogenetic trees were visualized with package
204 ggtree [35] implemented in R v 4.1.2. The new SARS-CoV genomes sequenced in this study
205 were submitted to either global initiative on sharing avian influenza data (GISAID,
206 <https://www.gisaid.org/>) or National Center for Biotechnology Information (NCBI,
207 <https://www.ncbi.nlm.nih.gov/>) and accession numbers provided in **Supplement Table 1**
208 and **Supplement Table 2**, respectively.

209

210 **Ethical approvals**

211 The COVID-19 surveillance and testing data was collected from public database of the
212 Kenya Ministry of Health (KMOH) with administrative approval from the ministry. Genomic
213 surveillance study was reviewed and approved by the KEMRI Scientific and Ethical Review
214 Unit (KEMRI/SERU/CVR/006/4035), ILRI Institutional Research Ethics Committee (ILRI-
215 IREC2020-52), and a reliance approval provided by Washington State University
216 Institutional Review Board based on in-country ethical reviews as provided for in Code of
217 Federal Regulations (45 C.F.R part 46 and 21 C.F.R. part 56). Data analysis and manuscript
218 development were in partnership with KMOH and KEMRI as demonstrated by authorship.

219

220

221 RESULTS

222 Pandemic waves and regional spread of infections

223 Between March 2020 and January 2022, Kenya experienced five waves of COVID-19 (**Figure**
224 **1**). Wave-1 and wave-2 occurred during the first phase of the pandemic before global
225 emergence of VoCs, wave-3 and wave-4 during second phase when VoCs emerged and
226 vaccination started, and wave-5 during the current phase of the pandemic after Kenya had
227 lifted most restrictions. Wave-2 was the longest at 10 weeks, while wave-1, wave-3, and
228 wave-4 lasted for 8 weeks each, and wave-5 for 7 weeks. The shortest inter-wave period of
229 4 weeks was observed between waves 1 and 2, while those between waves 2 and 3, waves
230 3 and 4, and waves 4 and 5 were 8 to 11 weeks long (**Figure 1**). Reported cases between
231 wave-3 and wave-4 were higher when compared to the cases reported between the other
232 waves.

233

234 The national attack rate (AR) during the waves ranged from 65.4 to 137.6 cases per 100,000
235 persons with the highest AR reported in wave-5 and the lowest in wave-1. During wave-1,
236 the median AR per county was 14.6 (Inter-quartile range =29.9) cases per 100,000 persons
237 across the countries 47 counties, with only 4 counties surrounding Nairobi city in
238 southcentral Kenya, and Mombasa city along the Indian Ocean coastal region reporting AR
239 >100 cases per 100,000 persons (**Figure 2**). In contrast, during wave-3 and wave-4, the
240 median AR rate was 70.3 (IQR = 98.5) cases per 100,000 persons, with 17 (36.2%) of the
241 counties reporting AR >100 cases per 100,000 persons. Overall, Nairobi city accounted for
242 43% of all the cases reported during the five waves (range 36.9% - 60.7%), and the highest
243 intra-wave AR ranging between 460.9 and 627.2 per 100,000 persons.

244

245 **Case fatality ratio**

246 The number of COVID-associated deaths reported was higher during the waves when
 247 compared to the number reported between the waves (**Figure 1**). Whereas the average CFR
 248 over the 23-month pandemic period was 1.7%, the intra-wave CFR 3.5%. Interestingly, while
 249 the intra-wave CFR was between 3.9% and 6.6% during waves 1-4, it dropped to 0.3% in
 250 wave 5. People aged below 20 years, who constitute >50% of the population contributed
 251 10.0% of cases but only 2.9% of deaths. In contrast, people aged ≥60 years old (4.2% of the
 252 population) contributed 13.7% of the cases and 56.5% of deaths (**Table 1**). Although only
 253 26.6% of the cases occurred in persons >49 years, this age group contributed 74.3% of the
 254 deaths. Reported deaths among males were almost twice higher than those reported
 255 among females (**Table 1**).

256

257 **Table 1: Categorization of COVID-19 cases and deaths by age groups and sex in Kenya**

| Age group | All Cases | | All deaths | | Female cases | Male cases | Male deaths | Female deaths |
|-----------|-----------|-----------------|------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | n | % (95% CI) | n | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) |
| 0-9 | 12064 | 3.8(3.7-3.8) | 89 | 1.6(1.3-2) | 43.7(42.8-44.6) | 56.3(55.4-57.2) | 65.2(54.3-74.8) | 34.8(25.2-45.7) |
| 10-19 | 19832 | 6.2(6.1- 6.3) | 72 | 1.3(1-1.6) | 47.6(46.9-48.3) | 52.4(51.7-53.1) | 58.3(46.1-69.6) | 41.7(30.4-53.9) |
| 20-29 | 60860 | 19(18.9-19.1) | 162 | 2.9(2.5-3.4) | 47.3(46.9-47.7) | 52.7(52.3-53.1) | 51.9(43.9-59.7) | 48.1(40.3-56.1) |
| 30-39 | 83067 | 25.9(25.8-26.1) | 428 | 7.7(7-8.4) | 43.1(42.8-43.5) | 56.9(56.5-57.2) | 51.9(47-56.7) | 48.1(43.3-53) |
| 40-49 | 59099 | 18.5(18.3-18.6) | 683 | 12.2(11.4-13.1) | 40.1(39.7-40.5) | 59.9(59.5-60.3) | 63.5(59.8-67.1) | 36.5(32.9-40.2) |
| 50-59 | 41394 | 12.9(12.8-13) | 996 | 17.8(16.9-18.9) | 41.5(41.1-42) | 58.5(58-58.9) | 68.4(65.4-71.2) | 31.6(28.8-34.6) |
| ≥60 | 43998 | 13.7(13.6-13.9) | 3152 | 56.5(55.2-57.8) | 44.2(43.8-44.7) | 55.8(55.3-56.2) | 64.6(62.9-66.3) | 35.4(33.7-37.1) |
| Total | 320314 | - | 5582 | - | 43.6(43.4-43.8) | 56.4(56.2-56.6) | 63.7(62.5-65) | 36.3(35-37.5) |

258

259

260 **Dominant SARS-CoV-2 lineages during waves**

261 The 1241 SARS-CoV-2 genomes sequenced between May 2020 and January 2022 were
262 assigned to 24 distinct Pango lineages with the most common lineages being B.1.617.2
263 (*Delta*, 38.4%), B.1(non-VOC, 24.6%), B.1.1.7 (*Alpha*, 16.5%), and B.1.1.529 (*Omicron*, 7.5%).

264

265 During the first phase of pandemic, the B.1 global parental lineage, which circulated from
266 the beginning of the pandemic in the country, dominated accounting for 94% of all genomes
267 in wave-1, and 71% in wave-2 (**Figure 3**). Diverse virus variants started emerging in wave-2
268 through to wave-3, both VoCs such as B.1.351 (*Beta*) and B.1.1.7 (*Alpha*) and non-VoCs such
269 as B.1.3x, B.1.5x, B.1.525 (*Eta*), A and A.23x. However, midway through wave-3, *Alpha*
270 emerged as dominant variant accounting for 74.9% of all genomes sequenced (**Figure 3 &**
271 **4**). The B.1.617.2 (*Delta*) and its sub-variant AY.x were first detected in March 2021 and
272 swept away other variants to become the dominant variant (99.3% of the genomes
273 sequenced) during wave-4 (**Figures 3 & 4**).

274

275

276 The B.1.1.529 (*Omicron*) lineage was first detected in Kenya in November 20, 2021 and by mid-
277 December it's sub-variant BA.1 become dominant accounting for 87.8% of all genomes sequenced
278 (**Figures 3 & 4**). Of the major VoCs, only *Beta*, *Alpha*, *Delta*, and *Omicron* were detected in the
279 Kenya samples sequenced. Genetic evolution analysis showed intra-lineage diversity of
280 various variants (**Figure 5**). Of the VoCs, *Delta* variant showed greater genetic diversity,
281 including multiple globally circulating AY.X lineages, consistent with multiple introductions

282 as depicted by the three divergent clusters (**Supplemental Figure 1, Figures 4 & 5**). This
283 analysis indicates that the *Alpha* variant and the *Omicron* have a closer common ancestor
284 compared to the *Delta* variant which appears to have diverged from a more distant ancestor
285 (**Figure 5**).

286

287

288 **DISCUSSION**

289 We used both classical and genomic epidemiologic approaches to track the COVID-19
290 pandemic in Kenya over 23 months (March 2020-January 2022) and assess the impact of
291 emerging virus variants on pandemic progression and severity in the country. In the first
292 phase of the pandemic, the country experienced two waves, characterized by national AR of
293 between 65.4 and 118.2 per 100,000 persons (Nairobi 404 – 474 cases per 100,000
294 persons), and CFR of 3.9 – 4.2%. The B.1 lineages of the virus dominated, except toward the
295 end of that period (January 2021) when *Alpha*, the first VoC in the country, was detected.
296 During this period, most cases were reported within and around the two main ports of entry
297 into Kenya, the capital city of Nairobi in the southcentral region that received most of the
298 international traveller, and Mombasa along the Indian ocean where most cargo deliveries to
299 the east Africa region are received (Figure 2).

300

301 The government responded to the waves by implementing various mitigation measures
302 including closure of borders, in-person schooling closures, and ban on social gatherings.
303 Most of these measures remained in place through October 2021 (18 months into the
304 pandemic), but they became less effective in preventing widespread infections in the
305 country in subsequent months when global VoCs started to emerge. The second phase
306 (March – October 2021) was characterized by emergence of imported VoCs and
307 introduction of COVID-19 vaccines in the country. Early in this period, *Alpha* and shortly
308 after *Delta* variants emerged and were associated with two major waves (wave-3 & wave-4).
309 The *Delta* variant dominated through 5 of the 8 months in this period, and the two waves
310 were associated with the high AR (national 115.6 – 125.7 per 100,000 persons, Nairobi
311 457.5 – 614.2 per 100,000 persons) and CFR (up to 6.6%). This period saw spread of

312 infections across all 47 counties in the country, but with the higher AR reported in Nairobi
313 and its surrounding counties. In addition to the early mitigation measures, lockdowns were
314 introduced for over 2 months in defined hotspot of the country characterized by high AR.
315 Interestingly, the March-October 2021 period was also marked by introduction of COVID-19
316 vaccines, albeit slowly, because of low vaccine availability in low-income countries globally.
317 During that 8 month-period, only 19% of the 27 million eligible Kenyans had received at
318 least one dose of the vaccine [18].

319

320 Since October 2021, Kenya has been in the third phase of pandemic characterized by lifting
321 of most restriction to re-open the economy and increased availability of vaccines. During
322 this phase in December 2021, the *Omicron* variant emerged, creating wave-5 associated
323 with the highest AR (national 137.6 per 100,000 persons, Nairobi 627.3 per 100,000
324 persons) but lowest CFR (CFR = 0.3%). The government did not re-introduce restrictions, and
325 vaccines became more widely available. By the end of January 2022, 42% of eligible Kenyans
326 had received at least one dose of the vaccine, but only 0.4% had received the recommended
327 3rd booster doses [36]. Overall, more deaths were experienced among the elderly people (60
328 years and above) compared to the younger people, a result comparable to global trends.

329

330 Of the >2,800 SARS-CoV-2 genomes reported from Kenya in the current and other recent
331 studies [37,38], there has been no VoC emerging from the country, with only B.1.525 (*Eta*)
332 that was detected in February 2021 in the Nairobi classified as variant of interest. Studies
333 point at increased transmissibility and capacity to evade the immune response as the key
334 factors associated with dominance of the VoCs [39,40]. There is raging public debate
335 associating vaccine inequity with emergence of these variants; however, the evidence so far

336 remains inconclusive. For instance, emergence of Delta from India and Omicron from South
337 Africa, countries that had low vaccination coverage at the time, appears to support this
338 hypothesis. However, the fact that we have not seen many VoCs emerging from Kenya and
339 other African countries apart from South Africa, most of them with <20% vaccine coverage
340 by end of 2021 does not support the argument. Studies suggest that new VoCs can
341 competitively gain advantage over existing variants through various mechanisms, including
342 having higher infectivity, longer duration of infection, or being less virulent to cause
343 asymptomatic disease that is harder to detect [6,41,42]. Breakthrough infections of
344 vaccinated individuals have been widespread with *Omicron*, however, a complete
345 vaccination regimen that includes the third booster dose improves virus neutralization
346 against the *Omicron* variant and may result in reduced transmission[43].

347

348 Our genomic analyses suggest multiple introductions of imported SARS-CoV-2 variants from
349 both regional and international sources. Though later waves were dominated by a single
350 imported VoC (*Alpha*, *Delta*, or *Omicron*), we detected subtypes of these major variants
351 associated with the US, Europe, India, Nigeria, DRC, and Uganda, supporting multiple
352 introductions. There are nearly 8 million SARS-CoV-2 genomes available in GISAID and more
353 than 50% of these sequences originate from just two regions, the North America and
354 Europe. Only about 1% of SARS-CoV-2 genomes are from Africa. Of these Africa genomes,
355 nearly 40% of sequences originate from South Africa (GISAID, accessed Feb 2nd, 2022). This
356 sampling bias reduces the likelihood that most African countries would have detected
357 emerging variants with consequential mutations in a timely manner. However, we expect
358 that if a VoC with sustained global impact emerged in the region, it could have been
359 detected through clinical disease profile or outside Africa in countries with more robust

360 genomic surveillance. The inter-wave duration ranged between 8-11 weeks for wave-2
361 through to wave-5, perhaps suggesting time to allow population immunity to wane and
362 support emergence of the next wave. Interestingly, the inter-wave period between wave-1
363 and wave-2 was only 4 weeks, likely reflecting the low level of the population immunity to
364 SARS-CoV-2 at the time.

365

366

367 A limitation of the study is that reported COVID-19 cases and deaths and samples used for
368 genomic surveillance were based on the KMOH surveillance, and which likely
369 underestimated the extent of the pandemic at any one time. Nonetheless, surveillance plays
370 a critical role in monitoring trends and control of global pandemics.

371

372 In conclusion, the emergence of *Alpha*, *Delta*, and *Omicron* VoCs was a turning point that
373 resulted in widespread and higher SARS-CoV-2 infections across the country, with varying
374 fatality rates. Enhanced genomic and molecular surveillance for SARS-CoV-2 in developing
375 countries can support early detection of VoCs and guide public health control measures
376 such application of mitigation measures.

377

378

379 **FUNDING**

380 This work was supported by US National Institute of Allergy and Infectious Disease/National
381 Institutes of Health (NIAID/NIH), grants number U01AI151799 and U01AI151799-02S1
382 through the Centre for Research in Emerging Infectious Diseases – East and Central Africa
383 (CREID-ECA). Funding was also provided by Research Program on Livestock of the
384 Consultative Group for International Agricultural Research, Rockefeller Foundation, Africa-
385 Centers for Disease Control and Prevention, Kenya Medical Research Institute Grant #
386 KEMRI/COV/SPE/012. Carolyne Nasimiyu was supported by the Fogarty International Center
387 and NIAID/NIH under grant number D43TW011519.

388

389 **ACKNOWLEDGEMENTS**

390 We thank Shebbar Osiany, Paul Dobi, Edward Nyaga, Collins. Muli, Regina Njeru, Reuben
391 Mwangi for supporting genomic work, Missiani Ochwoto, Ruth Cheruto, James Kimotho, and
392 Jeremiah Omar for supporting testing, and the Washington State University Global Health
393 Kenya staff for administrative support. The findings and conclusions in this study are those
394 of the authors and do not necessarily represent the official position of the Kenya MOH,
395 KEMRI, US NIH, or CGIAR/ILRI.

396

397

398 **CONFLICT OF INTEREST**

399 The authors declare they have no conflict of interest.

400

401

402 REFERENCES

- 403 1. Salyer SJ, Maeda J, Sembuche S, et al. The first and second waves of the COVID-19
404 pandemic in Africa: a cross-sectional study. *The Lancet*. Elsevier; **2021**;
405 397(10281):1265–1275.
- 406 2. Hale T, Angrist N, Hale AJ, et al. Government responses and COVID-19 deaths: Global
407 evidence across multiple pandemic waves. *PLoS One*. **2021**; 16(7):e0253116.
- 408 3. Jassat W, Mudara C, Ozougwu L, et al. Difference in mortality among individuals
409 admitted to hospital with COVID-19 during the first and second waves in South Africa:
410 a cohort study. *Lancet Glob Health*. **2021**; 9(9):e1216–e1225.
- 411 4. Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel
412 Therapeutics Against Coronavirus (COVID-19). *StatPearls* [Internet]. Treasure Island
413 (FL): StatPearls Publishing; 2022 [cited 2022 Jan 27]. Available from:
414 <http://www.ncbi.nlm.nih.gov/books/NBK570580/>
- 415 5. Konings F, Perkins MD, Kuhn JH, et al. SARS-CoV-2 Variants of Interest and Concern
416 naming scheme conducive for global discourse. *Nat Microbiol*. **2021**; 6(7):821–823.
- 417 6. Cantón R, Ramos PDL, García-Botella A, et al. New variants of SARS-CoV-2. *Rev Esp*
418 *Quimioter*. **2021**; 34(5):419–428.
- 419 7. Njenga MK, Dawa J, Nanyingi M, et al. Why is There Low Morbidity and Mortality of
420 COVID-19 in Africa? *Am J Trop Med Hyg*. **2020**; 103(2):564–569.
- 421 8. Ngere I, Dawa J, Hunsperger E, et al. sssHigh seroprevalence of SARS-CoV-2 but low
422 infection fatality ratio eight months after introduction in Nairobi, Kenya. *International*
423 *Journal of Infectious Diseases* [Internet]. **2021** [cited 2021 Sep 7]; . Available from:
424 <https://www.sciencedirect.com/science/article/pii/S1201971221006962>
- 425 9. McKibbin W, Fernando R. The Global Macroeconomic Impacts of COVID-19: Seven
426 Scenarios. *Asian Economic Papers*. **2021**; 20(2):1–30.
- 427 10. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of
428 concern in South Africa. *Nature*. **2021**; 592(7854):438–443.
- 429 11. Novelli G, Colona VL, Pandolfi PP. A focus on the spread of the delta variant of SARS-
430 CoV-2 in India. *Indian J Med Res*. **2021**; 153(5–6):537–541.
- 431 12. Silva JF da, Esteves RJ, Siza C, et al. Cluster of SARS-CoV-2 Gamma Variant Infections,
432 Parintins, Brazil, March 2021. *Emerg Infect Dis*. **2022**; 28(1):262–264.
- 433 13. Jansen L. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster —
434 Nebraska, November–December 2021. *MMWR Morb Mortal Wkly Rep* [Internet]. **2021**
435 [cited 2022 Feb 4]; 70. Available from:
436 <https://www.cdc.gov/mmwr/volumes/70/wr/mm705152e3.htm>

- 437 14. Yang S, Hemarajata P, Hilt EE, Price TK, Garner OB, Green NM. Investigation of SARS-
438 CoV-2 Epsilon Variant and Hospitalization Status by Genomic Surveillance in a Single
439 Large Health System During the 2020-2021 Winter Surge in Southern California. *Am J*
440 *Clin Pathol.* **2021**; :aqab203.
- 441 15. Wangari EN, Gichuki P, Abuor AA, et al. Kenya’s response to the COVID-19 pandemic: a
442 balance between minimising morbidity and adverse economic impact. *AAS Open Res.*
443 **2021**; 4:3.
- 444 16. Ngere I, Dawa J, Hunsperger E, et al. High seroprevalence of SARS-CoV-2 but low
445 infection fatality ratio eight months after introduction in Nairobi, Kenya. *Int J Infect Dis.*
446 **2021**; 112:25–34.
- 447 17. Brand SPC, Ojal J, Aziza R, et al. COVID-19 transmission dynamics underlying epidemic
448 waves in Kenya. *Science* [Internet]. American Association for the Advancement of
449 Science; **2021** [cited 2021 Dec 25]; . Available from:
450 <https://www.science.org/doi/abs/10.1126/science.abk0414>
- 451 18. MINISTRY OF HEALTH – REPUBLIC OF KENYA [Internet]. [cited 2021 Jun 9]. Available
452 from: <https://www.health.go.ke/>
- 453 19. Orangi S, Pinchoff J, Mwanga D, et al. Assessing the level and determinants of COVID-
454 19 Vaccine Confidence in Kenya [Internet]. 2021 Jun p. 2021.06.11.21258775. Available
455 from: <https://www.medrxiv.org/content/10.1101/2021.06.11.21258775v1>
- 456 20. Covid-19 vaccination: Campaign targeting public transport operators launched. –
457 MINISTRY OF HEALTH [Internet]. [cited 2022 Jan 7]. Available from:
458 [https://www.health.go.ke/covid-19-vaccination-campaign-targeting-public-transport-
459 operators-launched/](https://www.health.go.ke/covid-19-vaccination-campaign-targeting-public-transport-operators-launched/)
- 460 21. Kenya increases uptake and equity for COVID-19 vaccinations [Internet]. [cited 2022
461 Jan 7]. Available from: [https://www.who.int/news-room/feature-stories/detail/kenya-
462 increases-uptake-and-equity-for-covid-19-vaccinations](https://www.who.int/news-room/feature-stories/detail/kenya-increases-uptake-and-equity-for-covid-19-vaccinations)
- 463 22. Gohl DM, Garbe J, Grady P, et al. A rapid, cost-effective tailed amplicon method for
464 sequencing SARS-CoV-2. *BMC Genomics.* **2020**; 21(1):863.
- 465 23. Grubaugh ND, Gangavarapu K, Quick J, et al. An amplicon-based sequencing
466 framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar.
467 *Genome Biol.* **2019**; 20(1):8.
- 468 24. Releases · nf-core/viralrecon [Internet]. GitHub. [cited 2022 Jan 28]. Available from:
469 <https://github.com/nf-core/viralrecon/releases>
- 470 25. Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution.
471 *Bioinformatics.* **2018**; 34(23):4121–4123.

- 472 26. Nguyen L-T, Schmidt HA, Haeseler A von, Minh BQ. IQ-TREE: A Fast and Effective
473 Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. *Molecular*
474 *Biology and Evolution*. **2015**; 32(1):268–274.
- 475 27. FigTree [Internet]. [cited 2022 Jan 28]. Available from:
476 <http://tree.bio.ed.ac.uk/software/figtree/>
- 477 28. Kalyaanamoorthy S, Minh BQ, Wong TKF, Haeseler A von, Jermiin LS. ModelFinder: fast
478 model selection for accurate phylogenetic estimates. *Nat Methods*. **2017**; 14(6):587–
479 589.
- 480 29. Didelot X, Wilson DJ. ClonalFrameML: Efficient Inference of Recombination in Whole
481 Bacterial Genomes. *PLOS Computational Biology*. Public Library of Science; **2015**;
482 11(2):e1004041.
- 483 30. O’Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an
484 emerging pandemic using the pangolin tool. *Virus Evolution*. **2021**; 7(2):veab064.
- 485 31. Turakhia Y, Thornlow B, Hinrichs AS, et al. Ultrafast Sample placement on Existing
486 tRees (USHER) enables real-time phylogenetics for the SARS-CoV-2 pandemic. *Nat*
487 *Genet*. **2021**; 53(6):809–816.
- 488 32. Aksamentov I, Roemer C, Hodcroft E, Neher R. Nextclade: clade assignment, mutation
489 calling and quality control for viral genomes. *JOSS*. **2021**; 6(67):3773.
- 490 33. Hoang DT, Chernomor O, Haeseler A von, Minh BQ, Vinh LS. UFBoot2: Improving the
491 Ultrafast Bootstrap Approximation. *Molecular Biology and Evolution*. **2018**; 35(2):518–
492 522.
- 493 34. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic
494 analysis. *Virus Evolution*. **2018**; 4(1):vex042.
- 495 35. Yu G. Using ggtree to Visualize Data on Tree-Like Structures. *Current Protocols in*
496 *Bioinformatics*. **2020**; 69(1):e96.
- 497 36. MINISTRY OF HEALTH – REPUBLIC OF KENYA [Internet]. [cited 2021 Aug 23]. Available
498 from: <https://www.health.go.ke/>
- 499 37. Kimita G, Nyataya J, Omuseni E, et al. A genomics dissection of Kenya’s COVID-19
500 waves: temporal lineage replacements and dominance of imported variants of concern
501 [Internet]. 2021 [cited 2022 Jan 28]. Available from:
502 <https://europepmc.org/article/PPR/PPR408814>
- 503 38. Githinji G, Laurent ZR de, Mohammed KS, et al. Tracking the introduction and spread of
504 SARS-CoV-2 in coastal Kenya. *Nat Commun*. **2021**; 12(1):4809.
- 505 39. Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak
506 caused by the SARS-CoV-2 Delta variant [Internet]. medRxiv; 2021 [cited 2022 Jan 28].


- 507 p. 2021.07.07.21260122. Available from:
508 <https://www.medrxiv.org/content/10.1101/2021.07.07.21260122v2>
- 509 40. Grabowski F, Kočańczyk M, Lipniacki T. Omicron strain spreads with the doubling time
510 of 3.2—3.6 days in South Africa province of Gauteng that achieved herd immunity to
511 Delta variant [Internet]. medRxiv; 2021 [cited 2022 Jan 28]. p. 2021.12.08.21267494.
512 Available from: <https://www.medrxiv.org/content/10.1101/2021.12.08.21267494v1>
- 513 41. Quantifying competitive advantages of mutant strains in a population involving
514 importation and mass vaccination rollout. *Infectious Disease Modelling*. Elsevier; **2021**;
515 6:988–996.
- 516 42. Russell A, O’Connor C, Lasek-Nesselquist E, et al. Spatiotemporal analyses illuminate
517 the competitive advantage of a SARS-CoV-2 variant of concern over a variant of
518 interest [Internet]. medRxiv; 2021 [cited 2022 Feb 4]. p. 2021.09.14.21262977.
519 Available from: <https://www.medrxiv.org/content/10.1101/2021.09.14.21262977v1>
- 520 43. Garcia-Beltran WF, Lam EC, St. Denis K, et al. Multiple SARS-CoV-2 variants escape
521 neutralization by vaccine-induced humoral immunity. *Cell*. **2021**; 184(9):2372-2383.e9.

522

523

524

525 **LEGEND OF FIGURES**




526

527 **Figure 1.** Number of reported COVID-19 cases and deaths by epidemiological week, 2020-

528 2022, Kenya. The five waves are highlighted in different colours. The numbers of fatalities

529 are denoted by the red line graph with a secondary axis to the right.



530

531 **Figure 2.** SARS-CoV-2 attack rate by county and wave in Kenya.


532

533

534

535

536




537

538 **Figure 3.** Kenyan COVID-19 Epi-curve as of January 30, 2022, showing the dominant SARS-

539 CoV-2 variants during each of the 5 waves.

540



541

542 **Figure 4.** A time calibrated phylogenetic tree of 1241 SARS CoV-2 genomes sequenced from
543 Kenyan patients between May 2020 and December 2022. Pango lineage designations are
544 indicated by the circles on the branch tips, including VoCs and variants of interest as
545 designated by World Health Organization. Using the 2019 Wuhan-Hu-1 genome (GenBank
546 accession number MN908947.3) as the root of the tree.

547


548

549

550

551

552



553

554

555 **Figure 5:** Circular phylogenetic tree depicting evolutionary relationship of Kenyan SARS-CoV-

556 2 sequences (n=1241) against global genomes(n=894) clustered by pangolin lineage

557 annotation as shown in different background colours. The tree is rooted with the Wuhan

558 (MN908947.3) reference genome. Kenyan genomes are shown in green circular tips while

559 the global genomes are shown in blue tips. Lineages representing the major global variants

560 of concern (VoC) detected in Kenya are shown: B.1.1.7 (*Alpha*) is shown in pink background;

561 B.1.351(Beta) is shown in deep blue background; (B.1.617.2 (*Delta*) is shown in orange

562 background; B.1.1.529 (*Omicron*) is shown in red background.

563


564

565

566

567

568



569

570 **Supplement Figure 1.** Maximum likelihood tree showing global context of SARS-CoV-2 Delta

571 variants circulating in Nairobi, Kenya. Region of origin for each SARS-CoV-2 variant is

572 indicated by the colour of the circles at the branch tips.

573

574

575

576

577

578

579

580

581

582

583

584

585

586 **Supplement Table 1.** Accession number for the 1179 genomes sequenced in this study submitted to
587 global initiative on sharing avian influenza (GISAID) database (<https://www.gisaid.org/>).

588

589 **Supplement Table 2.** Accession number for the 62 genomes sequenced in this study submitted to
590 National Center for Biotechnology Information (NCBI) database (<https://www.ncbi.nlm.nih.gov/>).

591